title: [Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].
abstract: OBJECTIVE
  We investigated atorvastatin effectiveness and tolerance in HIV patients with hypercholesterolemia related to antiretroviral treatment.
  
  
  METHODS
  Prospective study that included HIV+ patients under antiretroviral treatment who displayed secondary dyslipemia and medical treatment criteria (according to NCEP-III). These patients were given 10 mg/day atorvastatin and hygienic-dietetic measures. If the therapeutic objectives were not achieved, the dose of atorvastatin was increased to 20 mg/day. Patients were followed up for 6 months.
  
  
  RESULTS
  32 patients were included. In 5 cases it was necessary to increase the dose from 10 mg atorvastatin to 20 mg. The therapeutic objective was obtained in 62% cases, with a good clinical tolerance. Only one adverse effect was noticed, which forced the removal of the drug.
  
  
  CONCLUSIONS
  In our study atorvastatin was effective for the treatment of dyslipemia in HIV patients, and it was safe and well tolerated.
authors.affiliation: Unitat de Malalties Infeccioses-VIH, Fundació Hospital-Asil de Granollers, Granollers, Barcelona, Spain.
authors.forename: Anna
authors.initials: A
authors.lastname: Soler
authors.forename: Elisabet
authors.initials: E
authors.lastname: Deig
authors.forename: Josep
authors.initials: J
authors.lastname: Guil
authors.forename: Marisa
authors.initials: M
authors.lastname: Rodríguez-Martín
authors.forename: Ana
authors.initials: A
authors.lastname: Guelar
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D000069059:Atorvastatin; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin